<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332017000200087</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2016.07.012</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación de costo-efectividad de los nuevos anticoagulantes orales en pacientes con fibrilación auricular no valvular]]></article-title>
<article-title xml:lang="en"><![CDATA[Cost-effectiveness assessment of new oral anticoagulation drugs in patients with non-valvular atrial fibrillation]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Peña]]></surname>
<given-names><![CDATA[Ángel Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<volume>24</volume>
<numero>2</numero>
<fpage>87</fpage>
<lpage>95</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332017000200087&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332017000200087&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332017000200087&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La fibrilación auricular es el trastorno más frecuente del ritmo cardíaco y una de las causas potencialmente tratables de cardioembolia y ataque cerebrovascular. La disponibilidad de nuevos anticoagulantes para pacientes con fibrilación auricular no valvular, plantea retos, derivados principalmente de los costos de su uso, perfiles de eficacia y seguridad, tolerancia y disponibilidad. Se llevó a cabo un análisis de costo-efectividad con base en un modelo de Markov, que permite comparar las estrategias de anticoagulación disponibles para fibrilación auricular no valvular en el país (apixabán, dabigatrán, rivaroxabán). La perspectiva empleada fue la del tercero pagador (sistema de salud colombiano), considerando solo costos médicos directos. Se siguieron las guías metodológicas para este tipo de estudios propuestas por ISPOR (International Society for Pharmacoeconomics and Outcomes Research) e INAHTA (International Network of Agencies for Health Technology Assessment). El horizonte temporal fue de 5 años, 10 años y toda la vida, en tanto que la tasa de descuento fue del 3%. Luego de la evaluación del modelo, con base en los análisis de sensibilidad realizados y el umbral de costo-efectividad para Colombia, se encontró que para el caso base, las diferentes moléculas evaluadas, si bien son costo-efectivas, exceden el umbral propuesto para este trabajo, siendo rivaroxabán y dabigatrán las únicas estrategias costo-efectivas con un horizonte temporal a 10 años con una tasa de descuento del 3% y para un horizonte temporal de toda la vida y tasa de descuento del 3%, las tres moléculas alcanzan el umbral de costo-efectividad establecido para Colombia. Dichas consideraciones son altamente sensibles al costo de los medicamentos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Atrial fibrillation is the most common heart rate disorder and one of the potentially treatable causes of cardioembolisms and cerebrovascular events. Availability of new anticoagulation drugs in patients with non-valvular atrial fibrillation poses challenges that mostly derive from usage costs, efficacy and security profiles, tolerance and availability. A cost-effectiveness analysis was conducted based on the Markov model, which allows to compare the available anticoagulation strategies for non-valvular atrial fibrillation in the country (apixaban, dabigatran, rivaroxaban). The third payer perspective (according to Colombian health system) was used, taking into consideration only the direct medical costs. The methodological guides followed were suggested by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Network of Agencies for Health Technology Assessment (INAHTA). The time frame was 5 years, 10 years and a lifetime, whilst the discount rate was 3%. After assessing the model based on the conducted sensitivity analysis and the cost-effectiveness threshold for Colombia, it was revealed that for the baseline case the different molecules assessed, despite being cost effective, exceed the threshold proposed for this study. Rivaroxaban and dabigatran are the only cost-effective strategies in a 10-year time frame with a discount rate of 3% and for a lifetime time frame and discount rate of 3% all three molecules reach the costeffectiveness threshold established for Colombia. These considerations are highly sensitive to the cost of the medications.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[Ictus]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento anticoagulante]]></kwd>
<kwd lng="es"><![CDATA[Análisis de costo-efectividad.]]></kwd>
<kwd lng="en"><![CDATA[Atrial fibrillation]]></kwd>
<kwd lng="en"><![CDATA[Stroke]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulation therapy]]></kwd>
<kwd lng="en"><![CDATA[Cost-effectiveness analysis.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>National Collaborating Centre for Chronic Conditions</collab>
<source><![CDATA[Atrial fibrillation: national clinical guideline for management in primary and secondary care]]></source>
<year>2006</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Royal College of Physicians]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guidelines for the management of atrial fibrillation the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
<name>
<surname><![CDATA[Schotten]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Savelieva]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>2010</year>
<volume>31</volume>
<page-range>2369-429</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wann]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[January]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Ellenbogen]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Lowe]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Estes]]></surname>
<given-names><![CDATA[NAM]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2011</year>
<volume>123</volume>
<page-range>104-23</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[January]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Wann]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Alpert]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Calkins]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cleveland]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Cigarroa]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>64</volume>
<page-range>2246-80</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guías de diagnóstico, tratamiento de la fibrilación auricular Sociedad Colombiana de Cardiología 2007]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2007</year>
<volume>14</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>51-184</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dabigatran versus warfarin in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oldgren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parekh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<page-range>1139-51</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rivaroxaban versus warfarin in nonvalvular atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Hacke]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[New Eng J Med]]></source>
<year>2011</year>
<page-range>883-91</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial design and rationale]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Khatib]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ansell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Easton]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[Am Heart J]]></source>
<year>2010</year>
<volume>159</volume>
<page-range>331-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Grandi]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Shimony]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Filion]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Eisenberg]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2012</year>
<volume>110</volume>
<page-range>453-60</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Phung]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Circ Cardiovasc Qual Outcomes]]></source>
<year>2012</year>
<volume>5</volume>
<page-range>711-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Population-based cohort study of warfarin-treated patients with atrial fibrillation incidence of cardiovascular and bleeding outcomes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[van Staa]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Murray-Thomas]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schoof]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Clemens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ackermann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ Open]]></source>
<year>2014</year>
<volume>4</volume>
<page-range>e003839</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social Colombia, Colciencias</collab>
<source><![CDATA[Guía de práctica clínica para el Síndrome Coronario Agudo. GPC-SCA.]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<collab>Ministerio de Salud y de Protección Social</collab>
<source><![CDATA[Guía de Práctica Clínica para la prevención detección temprana, diagnóstico, tratamiento y seguimiento de dislipidemias en adultos]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="">
<collab>Instituto de Evaluación Tecnológica en Salud (IETS).</collab>
<source><![CDATA[Análisis de costo-efectividad de dabigatrán, rivaroxabán y apixabán comparado con warfarina para prevención de fenómenos tromboembólicos e isquémicos en pacientes adultos con fibrilación auricular no valvular en Colombia.]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Costo-efectividad de dabigatrán comparado con warfarina para el tratamiento de pacientes con fibrilación auricular no valvular Rev Colomb]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Triana]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castañeda]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parada]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Otálora-Esteban]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiol]]></source>
<year>2016</year>
<volume>23</volume>
<page-range>82-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
